About: Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1999 (uk) article scientifique publié en 1999 (fr) im April 1999 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q56944980-57078E14-6E67-4843-AD91-0A60DD141E59
publication date	1999-04-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56944980-EDE90619-F65D-4209-BE5C-2053D728EF14
language of work or name	English
cites work	wds:Q56944980-14B10F6E-BED0-4965-8D30-2EF2E78DC6D4 wds:Q56944980-16FE2691-FADD-4C06-B69F-E0750A65CBF8 wds:Q56944980-3143F63A-AD7C-449F-8732-FE38923831FA wds:Q56944980-329DED2D-698A-4451-BA53-F4E6CFEF4C26 wds:Q56944980-3D129C0F-CBFD-4D2B-B3BE-6614742B5784 wds:Q56944980-3F5E2F3C-103C-4A28-A8DA-57CF4BE9D129 wds:Q56944980-4AC29BDA-17ED-4B4A-9FA2-14D83EAF2484 wds:Q56944980-523A17A5-83D2-4791-91FB-85CFD8BD7BCD wds:Q56944980-60E141C5-C02D-4DF8-8A05-6F71F62D3061 wds:Q56944980-611842D8-E732-4302-9C35-AEA7F5BD5D3E wds:Q56944980-64834B01-5CF6-4DA9-A079-3BFC782DA6C5 wds:Q56944980-69A4A486-31F5-4507-8BFA-44DF7FE8FFE9 wds:Q56944980-6F4B001C-2710-4550-99FD-8256DA7D4357 wds:Q56944980-7BC5FD1C-2AD5-4554-9E63-B4BA4F1AD71F wds:Q56944980-7DF46FFA-8CD8-4EE1-BFF9-0EA7331F6E0F wds:Q56944980-8F71F1BB-F8E6-45A7-B2D0-BB73ADAAEE75 wds:Q56944980-9654B322-CBC1-423C-9996-0EDB92F088D8 wds:Q56944980-9B6374C7-C5B3-442C-8700-94963E3D0977 wds:Q56944980-A9AC5FAF-8184-488A-86A7-C1E8DA9643CD wds:Q56944980-AF34CBE5-F00B-41D7-91B0-9417D85A9FD5 wds:Q56944980-B4540613-1DA0-42DA-974A-59EAA06A2556 wds:Q56944980-DB672832-4614-466E-AB57-4A24F8E3B6E7 wds:Q56944980-E1C4F7F6-FB0D-4437-B0B5-C395CBC18502 wds:Q56944980-EB34834F-66E6-4C94-9865-6C62DE4968A1 wds:Q56944980-F864BEA4-AA44-4C16-BB3F-75BC14EFA46C wds:Q56944980-F958F00D-1A15-4A85-ADFB-6C9EDB484D13 wds:Q56944980-FA1EF2CA-2B89-43B2-A3AF-F76AC2196BC1
cites work	Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt Sex difference in antithrombotic effect of aspirin Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. Development of aspirin resistance in persons with previous ischemic stroke. Are we mortgaging the medical profession? Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia Diagnosing and managing unstable angina. Agency for Health Care Policy and Research Previous aspirin use may attenuate the severity of the manifestation of acute ischemic syndromes Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration Final report on the aspirin component of the ongoing Physicians' Health Study A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened Stroke Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Antiplatelet agents in the prevention and therapy of thrombosis Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries Unstable angina or non-Q wave infarction despite long-term aspirin: response to thrombolytic therapy with implications on mechanisms Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Clinical and angiographic characteristics and outcome of patients with rest-unstable angina occurring during regular aspirin use. Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion Prospective Comparison of Patient Characteristics and Outcome of Non-prior Aspirin Users versus Aspirin Users with Unstable Angina or Non-Q-Wave Myocardial Infarction Treated with Combination Antithrombotic Therapy
author name string	wds:Q56944980-2708FE03-C00A-4002-AB88-9CCA6CC0298B wds:Q56944980-6BB020E9-C8CD-4269-A772-70541BACEC0B wds:Q56944980-702F2F3F-3BD2-4767-80EB-944BDDBFD939 wds:Q56944980-76B688F5-1941-4C12-9BAA-044F70319CF8 wds:Q56944980-951FDCBD-4020-4D27-AD8D-FB7F7F5041D3 wds:Q56944980-A6DD4D9E-1C12-4BF1-BE47-65059781C29E wds:Q56944980-C5694D59-08D8-4EC1-B660-DFB557135BBB wds:Q56944980-E075650E-E859-4808-A467-D33D0EFF2245
author name string	Robert H Tuttle Paul R Eisenberg Michael M Kitt Alan Guerci Janine Stepinska Jean B Boland Karl Karsh Peter Widimsky
rdfs:label	Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey (en) Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey (nl)
skos:prefLabel	Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey (en) Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey (nl)
name	Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey (en) Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey (nl)
author	wds:Q56944980-16EFAE34-8F23-4A79-861E-D9F436406430 wds:Q56944980-2E0ABBBB-F60E-4A6F-9790-3C0F5E45A710 wds:Q56944980-448E6947-A4F0-4233-A70A-03588EE814A7 wds:Q56944980-49610BF4-B09B-48B6-B46E-327481AD1228 wds:Q56944980-4B478EC0-C63B-43A6-BE61-612BCB5D0677 wds:Q56944980-7A8EC81E-1720-4413-A2AD-AA07D0496015 wds:Q56944980-86F17D18-CD90-4C46-92AB-7FF875123B82 wds:Q56944980-8C9358B9-875B-4CBF-87F1-9C7A2DB279F9 wds:Q56944980-A07E628C-D3D7-42D8-940F-64251A0169AA wds:Q56944980-BBFC106A-445C-4CF5-813E-FA377ABB9BA4 wds:Q56944980-E1DD6159-217A-49B3-9146-9B417F0140E3 wds:Q56944980-F0736CB1-B1D0-452F-9072-77CFB9ECFF61
author	Robert Califf Eric J. Topol

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software